Dapiprazole

Dapiprazole
Clinical data
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa601043
Pregnancy
category
  • B
Routes of
administration		Topical (eye drops)
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityNegligible when administered topically
Identifiers
IUPAC name
  • 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,5-a]pyridine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H27N5
Molar mass325.460 g·mol−1
3D model (JSmol)
SMILES
  • n1nc(n2c1CCCC2)CCN4CCN(c3ccccc3C)CC4
InChI
  • InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3 checkY
  • Key:RFWZESUMWJKKRN-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Dapiprazole (brand name Rev-Eyes) is an alpha-1 blocker. It is used to reverse mydriasis after eye examination.[1]

References

  1. ↑ Doughty MJ, Lyle WM (May 1992). "A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation". Optometry and Vision Science. 69 (5): 358–68. doi:10.1097/00006324-199205000-00005. PMID 1350669. S2CID 22781280.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.